Warfarin is a frequently prescribed drug for both the treatment and prevention of thromboembolic complications. Although many reports have been published over the past years in different populations worldwide, there is a fundamental gap in understanding whether variations in CYP2C9 and VKORC1 genes account for the inter-individual variability in response to warfarin that is observed in Puerto Rican patients. This study is a first step toward the development of DNA-driven personalized guidelines for warfarin dose optimization in Puerto Rican patients with thromboembolic complications. Guided by strong preliminary data, this application will pursuit two specific aims: 1) Develop a physiogenomic (PG)-driven admixture analysis of 350 samples from a population of warfarin-treated Puerto Rican patients using the PG array in order to study the pharmacogenetics of warfarin in Puerto Ricans and 2) Determine whether combinatorial CYP2C9 and VKORC1 genotypes are associated with clinical phenotypes during warfarin therapy in Puerto Rican patients. Under the first aim, 350 DNA specimens from warfarin-treated Puerto Rican patients who consent to participate in this study will be genotyped at large-scale using a novel Illumina-based PG-array of 222 candidate genes from relevant cardio-metabolic and neuro-endocrine pathways in order to examine the population structure of Puerto Ricans and create a reference database of individual admixture, allele frequencies, linkage disequilibrium (LD) and haplotypes for pharmacogenetics studies. Noteworthy, this information remains to be determined in Puerto Ricans. Under the second aim, demographic and clinically relevant non-genetic data will be retrospectively collected from medical records of these patients in order to perform an association analysis between their previously obtained CYP2C9 and VKORC1 genotypes and the corresponding time to achieve stable warfarin dosing following survival analysis techniques and Cox proportional hazards model. Accomplishment of this specific aim will also give the basis for developing a DNA-guided warfarin dosing algorithm in Puerto Rican by using these patients as a learning sample. The long-term goal is to generate valuable information from the genetic background of Puerto Ricans in order to further validate the pharmacogenetic-driven warfarin dosing algorithm for this admixed population. The proposed research is significant because it is expected to advance and expand understanding of how these clinically relevant variants affect the way people from an admixed, under-served population respond to warfarin. This is an important and under-investigated area of pharmacogenetics in minority populations that will have potential applicability to personalize warfarin therapy.
The Support of Competitive Research Program SC2 mechanism is intended to encourage pilot and developmental research projects by providing support for increasing competitiveness of faculty members at minority-serving institutions who are in their early stages of development and are seeking to gather preliminary data. The proposed studies will fill a gap in the pharmacogenetics of warfarin, providing new information on the prevalence of CYP2C9 (metabolism) and VKORC1 (sensitivity) polymorphisms in Puerto Ricans as well as their role in the warfarin response variability observed in this admixed population. I am a new investigator and faculty member at the University of Puerto Rico Medical Sciences Campus, a minority-serving institution, and this SC2-type pilot project is my first attempt to obtain external federal funds. This mechanism will support my initial career development as a pharmacogeneticist interested in better understanding the genetic basis of the observed drug response variability among Puerto Ricans, by conducting a pilot pharmacogenetic study in this under-served population that might address potential health disparities in the clinical management of warfarin therapy.
|Duconge, Jorge; Cadilla, Carmen L; Seip, Richard L et al. (2015) Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials. P R Health Sci J 34:175-7|
|Claudio-Campos, Karla; Duconge, Jorge; Cadilla, Carmen L et al. (2015) Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. Drug Metab Pers Ther 30:87-105|
|Gonzalez, Michael J; Miranda-Massari, Jorge R; Berdiel, Miguel J et al. (2014) High Dose Intraveneous Vitamin C and Chikungunya Fever: A Case Report. J Orthomol Med 29:154-156|
|ValentÃn, Isa I; Rivera, Giselle; Nieves-Plaza, Mariely et al. (2014) Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. P R Health Sci J 33:97-104|
|Orengo-Mercado, Carmelo; Nieves, Bianca; LÃ³pez, Lizbeth et al. (2013) Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population. J Pharmacogenomics Pharmacoproteomics 4:|
|Duconge, Jorge; Cadilla, Carmen L (2013) CYP2D6's functional status associated with the length of hospitalization stay in psychiatric patients: a twist in the tale or evidence that matters? Biomark Med 7:913-4|
|Valentin, Isa Ivette; Vazquez, Joan; Rivera-Miranda, Giselle et al. (2012) Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. Ann Pharmacother 46:208-18|
|Duconge, Jorge; RuaÃ±o, Gualberto (2012) 'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine. Pharmacogenomics 13:1097-100|
|Ramos, Alga S; Seip, Richard L; Rivera-Miranda, Giselle et al. (2012) Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics 13:1937-50|
|Duconge, Jorge; RuaÃ±o, Gualberto (2010) The Emerging Role of Admixture in the Pharmacogenetics of Puerto Rican Hispanics. J Pharmacogenomics Pharmacoproteomics 1:|